OBJECTIVES: This study sought to clarify the clinical and echocardiographic prognostic implication of @entity296 after transcatheter aortic valve replacement (TAVR). BACKGROUND: The clinical significance of cardiac biomarker elevation after TAVR remains unclear. METHODS: @entity1 treated with TAVR in the PARTNER (Placement of Aortic Transcatheter Valves) trial were divided into tertiles (T1, T2, T3) based on the difference between the values on post-procedure day 1 and the baseline values of 2  cardiac biomarkers: @entity6949 (  @entity6949 ); and @entity908 kinase-myocardial band (  CK-MB) fraction. @entity1 were stratified according to their access route: transfemoral (TF) (n  = 1,840) or transapical (TA) (n  = 1,173). RESULTS: At 30 days after TF-TAVR, @entity1 in the highest tertile (T3) of cardiac biomarker elevation had a higher rate of all-cause mortality (  @entity6949 : T3: 5.4% vs. T1: 0.5%, p  = 0.006;   CK-MB: T3: 5.7% vs. T1: 0.9%, p  = 0.006) and cardiovascular mortality (  @entity6949 : T3: 4.9% vs. T1: 0.5%, p  = 0.01;   CK-MB: T3: 3.9% vs. T1: 0.5%, p  = 0.02). At 1 year, only @entity1 in the highest CK-MB tertile had higher rates of all-cause (25.4% vs. 16.8%, p  = 0.02) and cardiovascular (10.3% vs. 5.0%) mortality. Multivariable analysis demonstrated that greater release of cardiac biomarkers was independently associated with increased mortality in the TF population. After TA-TAVR, being in the highest tertile of cardiac biomarker elevation had no influence on clinical and echocardiographic outcomes at 30 days and 1 year. CONCLUSIONS: After TF-TAVR, a greater degree of @entity296 was associated with higher rates of 30-day all-cause and cardiovascular mortality. At 1 year, being in the highest tertile of   CK-MB was correlated with a higher rate of all-cause and cardiac mortality. Finally, the level of @entity296 after TA-TAVR had no impact on clinical and echocardiographic outcomes.

Clinical and Functional Outcomes Associated With XXXX After  Transfemoral and Transapical Transcatheter Aortic Valve Replacement: A Subanalysis From the PARTNER Trial (Placement of Aortic Transcatheter Valves).

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine'] @entity296 :: ('MESH:D009202', 'Disease') :: ['myocardial injury'] @entity6949 :: ('7137', 'Gene') :: ['cTnI', 'cardiac troponin I']
@entity296 :: (MESH:D009202,Disease) :: ['Myocardial Injury']
